Higher losses reported at EpiCept

August

EpiCept Corp. of Eastview reported higher second-quarter losses after its successful challenge of European regulatorsâ€™ negative opinion of its leukemia treatment Ceplene.
EpiCept said it had a net loss of $7.77 million, or 15 cents a share, on revenue of $42,000. For the comparable quarter a year earlier, it had a net loss of $7.04 million, or 22 cents a share, on revenue of $100,000. The weighted average of outstanding common stock rose from 32.4 million shares to 52 million shares in the period.

This entry was posted on Monday, August 11th, 2008 at 3:49 pm by Jerry Gleeson.
You can follow any responses to this entry through the RSS 2.0 feed.
Share and Enjoy: | Print Print | Email Email

It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the Terms of Service.

Business in the Burbs

Movers, shakers and newsmakers